Reaction of human skin chymotrypsin-like proteinase chymase with plasma proteinase inhibitors. 1989

N M Schechter, and J L Sprows, and O L Schoenberger, and G S Lazarus, and B S Cooperman, and H Rubin
Department of Dermatology, University of Pennsylvania, Philadelphia 19104.

The ability of plasma proteinase inhibitors to inactivate human chymase, a chymotrypsin-like proteinase stored within mast cell secretory granules, was investigated. Incubation with plasma resulted in over 80% inhibition of chymase hydrolytic activity for small substrates, suggesting that inhibitors other than alpha 2-macroglobulin were primarily responsible for chymase inactivation. Depletion of specific inhibitors from plasma by immunoadsorption using antisera against individual inhibitors established that alpha 1-antichymotrypsin (alpha 1-AC) and alpha 1-proteinase inhibitor (alpha 1-PI) were responsible for the inactivation. Characterization of the reaction between chymase and each inhibitor demonstrated in both cases the presence of two concurrent reactions proceeding at fixed relative rates. One reaction, which led to inhibitor inactivation, was about 3.5 and 4.0-fold faster than the other, which led to chymase inactivation. This was demonstrated in linear titrations of proteinase activity which exhibited endpoint stoichiometries of 4.5 (alpha 1-AC) and 5.0 (alpha 1-PI) instead of unity, and SDS gels of reaction products which exhibited a banding pattern indicative of both an SDS-stable proteinase-inhibitor complex and two lower Mr inhibitor degradation products which appear to have formed by hydrolysis within the reactive loop of each inhibitor. At inhibitor concentrations approaching those in plasma where inhibitor to chymase concentration ratios were in far excess of 4.5 and 5.0, the rate of chymase inactivation by both serpin inhibitors appeared to follow pseudo-first order kinetics. The "apparent" second order rate constants of inactivation determined from these data were about 3000-fold lower than the rate constants reported for human neutrophil cathepsin G and elastase with alpha 1-AC and alpha 1-PI, respectively. This suggests that chymase would be inhibited about 650-fold more slowly than these proteinases when released into plasma. These studies demonstrate that although chymase is inactivated by serpin inhibitors of plasma, both inhibitors are better substrates for the proteinase than they are inhibitors. This finding along with the slow rates of inactivation indicates that regulation of human chymase activity may not be a primary function of plasma.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D011480 Protease Inhibitors Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES). Antiprotease,Endopeptidase Inhibitor,Endopeptidase Inhibitors,Peptidase Inhibitor,Peptidase Inhibitors,Peptide Hydrolase Inhibitor,Peptide Hydrolase Inhibitors,Peptide Peptidohydrolase Inhibitor,Peptide Peptidohydrolase Inhibitors,Protease Antagonist,Protease Antagonists,Antiproteases,Protease Inhibitor,Antagonist, Protease,Antagonists, Protease,Hydrolase Inhibitor, Peptide,Hydrolase Inhibitors, Peptide,Inhibitor, Endopeptidase,Inhibitor, Peptidase,Inhibitor, Peptide Hydrolase,Inhibitor, Peptide Peptidohydrolase,Inhibitor, Protease,Inhibitors, Endopeptidase,Inhibitors, Peptidase,Inhibitors, Peptide Hydrolase,Inhibitors, Peptide Peptidohydrolase,Inhibitors, Protease,Peptidohydrolase Inhibitor, Peptide,Peptidohydrolase Inhibitors, Peptide
D002918 Chymotrypsin A serine endopeptidase secreted by the pancreas as its zymogen, CHYMOTRYPSINOGEN and carried in the pancreatic juice to the duodenum where it is activated by TRYPSIN. It selectively cleaves aromatic amino acids on the carboxyl side. Alpha-Chymotrypsin Choay,Alphacutanée,Avazyme
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006863 Hydrogen-Ion Concentration The normality of a solution with respect to HYDROGEN ions; H+. It is related to acidity measurements in most cases by pH pH,Concentration, Hydrogen-Ion,Concentrations, Hydrogen-Ion,Hydrogen Ion Concentration,Hydrogen-Ion Concentrations
D012697 Serine Endopeptidases Any member of the group of ENDOPEPTIDASES containing at the active site a serine residue involved in catalysis. Serine Endopeptidase,Endopeptidase, Serine,Endopeptidases, Serine
D012867 Skin The outer covering of the body that protects it from the environment. It is composed of the DERMIS and the EPIDERMIS.
D014357 Trypsin A serine endopeptidase that is formed from TRYPSINOGEN in the pancreas. It is converted into its active form by ENTEROPEPTIDASE in the small intestine. It catalyzes hydrolysis of the carboxyl group of either arginine or lysine. EC 3.4.21.4. Tripcellim,Trypure,beta-Trypsin,beta Trypsin
D015842 Serine Proteinase Inhibitors Exogenous or endogenous compounds which inhibit SERINE ENDOPEPTIDASES. Serine Endopeptidase Inhibitor,Serine Endopeptidase Inhibitors,Serine Protease Inhibitor,Serine Protease Inhibitors,Serine Proteinase Antagonist,Serine Proteinase Antagonists,Serine Proteinase Inhibitor,Serine Proteinase Inhibitors, Endogenous,Serine Proteinase Inhibitors, Exogenous,Serine Protease Inhibitors, Endogenous,Serine Protease Inhibitors, Exogenous,Antagonist, Serine Proteinase,Endopeptidase Inhibitor, Serine,Inhibitor, Serine Endopeptidase,Inhibitor, Serine Protease,Inhibitor, Serine Proteinase,Protease Inhibitor, Serine,Proteinase Antagonist, Serine,Proteinase Inhibitor, Serine
D015843 Serpins A family of serine proteinase inhibitors which are similar in amino acid sequence and mechanism of inhibition but differ in their specificity toward proteolytic enzymes. Some members of the serpin family may be substrates rather than inhibitors of SERINE ENDOPEPTIDASES. Serpin,Serpin Superfamily,Serpin Peptidase Inhibitors,Serpin Protease Inhibitors,Inhibitors, Serpin Peptidase,Inhibitors, Serpin Protease,Peptidase Inhibitors, Serpin,Protease Inhibitors, Serpin,Superfamily, Serpin

Related Publications

N M Schechter, and J L Sprows, and O L Schoenberger, and G S Lazarus, and B S Cooperman, and H Rubin
May 1987, The Journal of biological chemistry,
N M Schechter, and J L Sprows, and O L Schoenberger, and G S Lazarus, and B S Cooperman, and H Rubin
October 1972, Hoppe-Seyler's Zeitschrift fur physiologische Chemie,
N M Schechter, and J L Sprows, and O L Schoenberger, and G S Lazarus, and B S Cooperman, and H Rubin
January 2010, Hypertension in pregnancy,
N M Schechter, and J L Sprows, and O L Schoenberger, and G S Lazarus, and B S Cooperman, and H Rubin
June 1986, Analytical biochemistry,
N M Schechter, and J L Sprows, and O L Schoenberger, and G S Lazarus, and B S Cooperman, and H Rubin
January 1983, Annual review of biochemistry,
N M Schechter, and J L Sprows, and O L Schoenberger, and G S Lazarus, and B S Cooperman, and H Rubin
March 1973, Journal of reproduction and fertility,
N M Schechter, and J L Sprows, and O L Schoenberger, and G S Lazarus, and B S Cooperman, and H Rubin
September 1993, Biological chemistry Hoppe-Seyler,
N M Schechter, and J L Sprows, and O L Schoenberger, and G S Lazarus, and B S Cooperman, and H Rubin
August 1986, Journal of immunology (Baltimore, Md. : 1950),
N M Schechter, and J L Sprows, and O L Schoenberger, and G S Lazarus, and B S Cooperman, and H Rubin
May 1997, The Biochemical journal,
N M Schechter, and J L Sprows, and O L Schoenberger, and G S Lazarus, and B S Cooperman, and H Rubin
March 1996, The Journal of nutrition,
Copied contents to your clipboard!